Vaccine Interventions against the H5N1 Virus: Efficacy, Safety, and Implications for Public Health

Authors

  • Gabriel Vitor Romão de Oliviera Universidade de São Paulo
  • Gabryel Crispim de Farias Lück Universidade de São Paulo

Keywords:

H5N1, vacinas adjuvadas, imunogenicidade, saúde pública

Abstract

This qualitative review evaluates vaccine interventions against the H5N1 virus, focusing on efficacy and safety. Adjuvanted vaccines exhibit high immunogenicity and potential for cross-protection against viral variants, making them promising tools. However, challenges include reactogenicity — local or systemic adverse reactions — and scalability for mass production. The exclusion of vulnerable groups, such as pregnant women, from clinical trials limits the findings’ applicability to diverse populations. Ethical and epidemiological concerns also arise, underscoring the need for ongoing surveillance to track outbreaks. The study highlights innovative technologies, like mRNA platforms, as future solutions for rapid pandemic response. Combining effective vaccines, inclusive strategies, and technological advances is vital to reduce public health risks.

References

CHANTHAVANICH, P. et al. Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects. Vaccine, v. 39, n. 47, p. 6930-6935, 2021. DOI: 10.1016/j.vaccine.2021.10.010.

CHEN, X. et al. Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. BMC Medicine, v. 18, n. 1, 377, 2020. DOI: 10.1186/s12916-020-01836-y.

CHENG, M. P. et al. Acute cardiac injury in coronavirus disease 2019 and other viral infections—a systematic review and meta-analysis. Critical Care Medicine, v. 49, n. 9, p. 1558-1566, 2021. DOI: 10.1097/CCM.0000000000005026.

EL SAHLY, H. M. et al. Topical imiquimod does not provide an adjuvant effect when administered with inactivated influenza A/H5N1 vaccine in healthy young adults. Journal of Infectious Diseases, v. 224, n. 10, p. 1712-1719, 2021. DOI: 10.1093/infdis/jiab206.

ENDO, M. et al. Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform. Influenza and Other Respiratory Viruses, v. 14, n. 5, p. 551-563, 2020. DOI: 10.1111/irv.12755.

HOWARD, L. M. et al. Metabolomic signatures differentiate immune responses in avian influenza vaccine recipients. Journal of Infectious Diseases, v. 230, n. 3, p. 716-725, 2024. DOI: 10.1093/infdis/jiad611.

KIM, J. H. et al. Immunogenicity and safety of AS03-adjuvanted H5N1 influenza vaccine in children 6-35 months of age: results from a phase 2, randomized, observer-blind, multicenter, dose-ranging study. Pediatric Infectious Disease Journal, v. 40, n. 9, p. e333-e339, 2021. DOI: 10.1097/INF.0000000000003247.

MATSUDA, K. et al. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. Journal of Clinical Investigation, v. 131, n. 5, e140794, 2021. DOI: 10.1172/JCI140794.

NTAKIYISUMBA, E. et al. Prevalence, seroprevalence and risk factors of avian influenza in wild bird populations in Korea: a systematic review and meta-analysis. Viruses, v. 15, n. 2, 472, 2023. DOI: 10.3390/v15020472.

OLBEI, M. et al. SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients. Frontiers in Immunology, v. 12, 629193, 2021. DOI: 10.3389/fimmu.2021.629193.

PURCELL, R. et al. Systematic review of avian influenza virus infection and outcomes during pregnancy. Emerging Infectious Diseases, v. 31, n. 1, p. 50-56, 2025. DOI: 10.3201/eid3101.241343.

TIAN, C. et al. Risk factors and protective measures for healthcare worker infection during highly infectious viral respiratory epidemics: a systematic review and meta-analysis. Infection Control & Hospital Epidemiology, v. 43, n. 5, p. 639-650, 2022. DOI: 10.1017/ice.2021.18.

WIMMERS, F. et al. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell, v. 184, n. 15, p. 3915-3935.e21, 2021. DOI: 10.1016/j.cell.2021.05.039.

YUAN, K. et al. Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review. Molecular Psychiatry, v. 26, n. 9, p. 4982-4998, 2021. DOI: 10.1038/s41380-021-01036-x.

ZHANG, K. et al. Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis. Human Vaccines & Immunotherapeutics, v. 17, n. 2, p. 475-484, 2021. DOI: 10.1080/21645515.2020.1777822.

ZHOU, F. et al. Matrix M adjuvanted H5N1 vaccine elicits broadly neutralizing antibodies and neuraminidase inhibiting antibodies in humans that correlate with in vivo protection. Frontiers in Immunology, v. 12, 747774, 2021. DOI: 10.3389/fimmu.2021.747774.

Downloads

Published

2025-04-12

How to Cite

de Oliviera, G. V. R., & Lück, G. C. de F. (2025). Vaccine Interventions against the H5N1 Virus: Efficacy, Safety, and Implications for Public Health. Journal of Convergent Scientific Inquiry, 1(2), 35–45. Retrieved from https://jcsi.ufrdj.com/index.php/jcsi/article/view/13

Issue

Vol. 1 No. 2 (2025): Journal of Convergent Scientific Inquiry

Section

Revisão Narrativa ou Integrativa

License

Copyright (c) 2025 Journal of Convergent Scientific Inquiry

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Direitos de Publicação e Licença

© Acesso Aberto. Este artigo está licenciado sob a Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional (CC BY-NC-ND 4.0), que permite uso, compartilhamento, distribuição e reprodução em qualquer meio ou formato, exclusivamente para fins não comerciais, desde que: (1) os autores originais e a fonte sejam devidamente creditados; (2) seja fornecido o link para a licença Creative Commons; e (3) seja indicado se alterações foram realizadas no material licenciado. Não é permitido compartilhar material adaptado derivado deste artigo ou de partes dele. As imagens e demais materiais de terceiros incluídos neste artigo estão cobertos pela mesma licença CC BY-NC-ND 4.0, salvo indicação contrária na linha de crédito do respectivo material. Caso o material não esteja coberto por esta licença ou o uso pretendido não seja permitido por disposição legal ou exceda o uso autorizado, a permissão deverá ser obtida diretamente junto ao titular dos direitos autorais. Para visualizar uma cópia desta licença, acesse: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.pt .

Solicitação de Retirada de Artigos

Caso o(a) autor(a) deseje retirar o artigo antes da publicação, deverá encaminhar solicitação por escrito para o Editor-Chefe no endereço eletrônico editoraljcsi@gmail.com, com antecedência mínima de 20 dias da data prevista de publicação online. Após esse prazo, ou caso o artigo já tenha sido publicado, a retirada será permitida apenas em situações excepcionais, como comprovação de plágio ou fraude, a critério da equipe editorial.